Rohto Pharmaceutical Co.,Ltd. (TYO:4527)
Japan
· Delayed Price · Currency is JPY 2,178.50
-263.00 (-10.77%)
May 14, 2025, 3:30 PM JST
Rohto Pharmaceutical Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
| Revenue | 308,625 | 270,840 | 238,664 | 199,646 | 181,287 | Upgrade
|
| Revenue Growth (YoY) | 13.95% | 13.48% | 19.54% | 10.13% | -3.74% | Upgrade
|
| Cost of Revenue | 133,686 | 113,554 | 101,243 | 83,157 | 74,560 | Upgrade
|
| Gross Profit | 174,939 | 157,286 | 137,421 | 116,489 | 106,727 | Upgrade
|
| Selling, General & Admin | 115,521 | 101,377 | 89,859 | 76,435 | 73,933 | Upgrade
|
| Research & Development | 14,912 | 13,390 | 11,065 | 8,740 | 7,903 | Upgrade
|
| Operating Expenses | 135,999 | 117,119 | 103,883 | 88,297 | 84,860 | Upgrade
|
| Operating Income | 38,940 | 40,167 | 33,538 | 28,192 | 21,867 | Upgrade
|
| Interest Expense | -949 | -196 | -247 | -248 | -145 | Upgrade
|
| Interest & Investment Income | 1,779 | 2,009 | 2,285 | 751 | 1,532 | Upgrade
|
| Earnings From Equity Investments | 166 | -289 | 56 | 143 | 396 | Upgrade
|
| Currency Exchange Gain (Loss) | 516 | 447 | - | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | -20 | 294 | -64 | 245 | 260 | Upgrade
|
| EBT Excluding Unusual Items | 40,432 | 42,432 | 35,568 | 29,083 | 23,910 | Upgrade
|
| Gain (Loss) on Sale of Investments | 1,896 | -798 | -160 | -368 | 787 | Upgrade
|
| Gain (Loss) on Sale of Assets | -175 | - | - | - | - | Upgrade
|
| Asset Writedown | - | -348 | -1,338 | -892 | -1,691 | Upgrade
|
| Other Unusual Items | 179 | 230 | 219 | 129 | - | Upgrade
|
| Pretax Income | 42,332 | 41,516 | 34,289 | 27,952 | 23,006 | Upgrade
|
| Income Tax Expense | 11,380 | 10,123 | 7,860 | 6,803 | 6,236 | Upgrade
|
| Earnings From Continuing Operations | 30,952 | 31,393 | 26,429 | 21,149 | 16,770 | Upgrade
|
| Minority Interest in Earnings | 54 | -457 | -52 | -131 | -27 | Upgrade
|
| Net Income | 31,006 | 30,936 | 26,377 | 21,018 | 16,743 | Upgrade
|
| Net Income to Common | 31,006 | 30,936 | 26,377 | 21,018 | 16,743 | Upgrade
|
| Net Income Growth | 0.23% | 17.28% | 25.50% | 25.53% | 8.65% | Upgrade
|
| Shares Outstanding (Basic) | 228 | 228 | 228 | 228 | 228 | Upgrade
|
| Shares Outstanding (Diluted) | 229 | 229 | 229 | 229 | 229 | Upgrade
|
| Shares Change (YoY) | 0.06% | - | -0.00% | - | 0.01% | Upgrade
|
| EPS (Basic) | 136.11 | 135.60 | 115.62 | 92.13 | 73.39 | Upgrade
|
| EPS (Diluted) | 135.44 | 135.21 | 115.29 | 91.86 | 73.18 | Upgrade
|
| EPS Growth | 0.17% | 17.28% | 25.50% | 25.53% | 8.65% | Upgrade
|
| Free Cash Flow | - | 26,266 | 22,451 | 16,983 | 11,287 | Upgrade
|
| Free Cash Flow Per Share | - | 114.80 | 98.13 | 74.23 | 49.33 | Upgrade
|
| Dividend Per Share | - | 27.000 | 22.000 | 18.000 | 14.000 | Upgrade
|
| Dividend Growth | - | 22.73% | 22.22% | 28.57% | 7.69% | Upgrade
|
| Gross Margin | 56.68% | 58.07% | 57.58% | 58.35% | 58.87% | Upgrade
|
| Operating Margin | 12.62% | 14.83% | 14.05% | 14.12% | 12.06% | Upgrade
|
| Profit Margin | 10.05% | 11.42% | 11.05% | 10.53% | 9.24% | Upgrade
|
| Free Cash Flow Margin | - | 9.70% | 9.41% | 8.51% | 6.23% | Upgrade
|
| EBITDA | 47,627 | 48,854 | 41,339 | 35,865 | 28,615 | Upgrade
|
| EBITDA Margin | 15.43% | 18.04% | 17.32% | 17.96% | 15.78% | Upgrade
|
| D&A For EBITDA | 8,687 | 8,687 | 7,801 | 7,673 | 6,748 | Upgrade
|
| EBIT | 38,940 | 40,167 | 33,538 | 28,192 | 21,867 | Upgrade
|
| EBIT Margin | 12.62% | 14.83% | 14.05% | 14.12% | 12.06% | Upgrade
|
| Effective Tax Rate | 26.88% | 24.38% | 22.92% | 24.34% | 27.11% | Upgrade
|
| Advertising Expenses | 57,506 | 54,219 | 46,467 | 38,114 | 40,525 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.